Adenosine monophosphate-activated protein kinase (AMPK) regulates lipid, cholesterol and glucose metabolism in specialized metabolic tissues, such as muscle, liver and adipose tissue.
Introduction:
Hepatic fibrosis underlies most forms of chronic liver disease (1, 2), the 12 th most common cause of death in the United States (3) . The main causes of hepatic fibrosis in industrialized countries include chronic hepatitis C virus (HCV) infection, alcohol abuse, and nonalcoholic fatty liver disease (NAFLD) (4) . NAFLD has emerged as a considerable public health concern, as its major risk factors, obesity and insulin resistance, have reached epidemic proportions worldwide.
Furthermore, conditions that induce hepatic fibrosis, such as HCV and hepatitis B infection, alcoholism, and NAFLD, are the most common risk factors for the development of hepatocellular carcinoma (HCC) (5) , suggesting that therapeutic intervention for liver fibrosis may hold great value in the prevention of HCC.
Independent of etiology, chronic liver disease follows a common progression from inflammation to fibrosis, and finally to cirrhosis. Hepatocyte damage often serves as a triggering event in the pathogenesis of liver fibrosis, which initiates a complex crosstalk between hepatocytes and nonparenchymal liver cells. Injured or apoptotic hepatocytes can directly activate HSCs (reviewed in (6) ) and also release reactive oxygen species (ROS) and cytokines, leading to recruitment of inflammatory immune cells and to activation of resident macrophages (Kupffer cells) (7) .
Activated Kupffer cells and injured hepatocytes also secrete profibrogenic cytokines, including tumor necrosis factor-α (TNF-α), transforming growth factor-β1 (TGFβ1), and fibroblast growth factor (FGF), which stimulate the activation of hepatic stellate cells (HSC) (8) . HSC reside in the space of Disse; in normal liver HSC are quiescent and are characterized in part by the presence of cytoplasmic lipid droplets, which serve as the major site of retinol storage. In response to hepatic injury, HSC undergo rapid activation, and transdifferentiate into myofibroblast-like cells with a multitude of acquired morphological and functional properties.
chronic HSC activation results in excessive ECM accumulation, destruction of liver cytoarchitecture, and eventually to cirrhosis and liver failure (4) . The extent and duration of HSC activation are naturally limited by senescence; in mice lacking key senescence mediators, HSCs undergo aberrant proliferation in response to hepatic damage, leading to excessive liver fibrosis (10) . Pharmacologic means by which to limit the activation state of HSC, by inhibiting proliferation or promoting senescence or apoptosis, therefore represents an appealing therapeutic avenue in chronic liver disease. Further, given the established connection between HSC activation and hepatic fibrosis (6) , and the implications of hepatic fibrosis in the development of HCC as described above, strategies to limit HSC activation may also be of value for cancer prevention.
While insulin resistance has long been implicated in the progression of hepatic fibrosis, the molecular mechanisms underlying this relationship remain unclear. Adiponectin, a hormone secreted by adipose tissue, is markedly decreased in plasma under conditions of obesity and type 2 diabetes and adiponectin levels are directly correlated with insulin sensitivity, and inversely with the presence of metabolic syndrome (11, 12) . Administration of adiponectin ameliorates liver damage during experimental steatohepatitis and reduces the development of fibrosis (13, 14) . In agreement with these findings, adiponectin has been shown to decrease proliferation, migration, and fibrogenic gene expression and to induce apoptosis in activated HSC (14, 15) . Subsequent studies determined that adiponectin principally inhibits profibrogenic actions of HSC via adenosine monophosphate-activated protein kinase (AMPK) (16, 17) , a known downstream effector through which adiponectin induces glucose utilization and fatty acid oxidation (18) .
AMPK is an energy sensor that maintains cellular energy homeostasis in response to various stimuli including stress conditions, nutrient deprivation, exercise, and adipocyte-derived hormones (19, 20) . AMPK can also be activated pharmacologically by 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) and by metformin, a widely used anti-diabetic drug (21, 22) . Drugs that activate AMPK have well-established beneficial effects on liver glucose and lipid metabolism, which may augment their antifibrogenic properties. In HSCs, AMPK is thought to oppose activation by inhibiting the mTOR pathway, a known AMPK target (23) , and perhaps by inhibiting NF-κB (16) . AICAR and metformin also inhibit platelet-derived growth factor (PDGF)-induced proliferation and migration in activated HSC (17 A260/280 ratios were determined by a NanoDrop ND-1000 spectrophotometer and the integrity of the total RNA was verified using a Bioanalyzer (Agilent Technologies). 500 ng of deoxyribonuclease-treated total RNA was reverse transcribed into cDNA using SuperScript III reverse transcriptase (Invitrogen). Quantification of mRNA expression was performed by quantitative real-time PCR (qPCR) using a StepOnePlus qPCR platform (Applied Biosystems).
The following primer pairs were used for the amplification of genes of interest: Ponceau S solution (Sigma). After removing the stain by washing in water, the membrane was probed with monoclonal antibodies (phopho-AMPK or phosphor-S6RP at 1/250; Chemicon) in PBS overnight at 4°C, followed by anti-rabbit peroxidase-conjugate (1/10,000; Sigma) for 1 h at 22°C. Immunoreactive bands were detected by chemiluminesence (Lumi-Light PLUS ; Roche Diagnostics). In addition to Ponceau S staining, the membranes were also probed with β-actin or CTGF antibodies for loading control. 
Results

AICAR and metformin have distinct effects on quiescent hepatic stellate cell survival but identical impact on AMPK activation and inhibition of mTOR pathway
Previously published studies have focused on the effect of AMPK activation in activated HSC.
The results from these studies were promising in that AMPK activating agents AICAR and metformin inhibited proliferation and profibrogenic activity while promoting apoptosis of activated HSC (16, 17) . The effect of AMPK activation in quiescent HSC was the focus of this study. To determine the effect of AMPK activation on quiescent HSC survival, primary rat HSC maintained in culture for 48h were treated with AICAR or metformin, and cell viability was assessed. HSCs treated with AICAR for 24h showed dramatic induction of cell death even at the lowest concentration used (100μM), while metformin-treated HSCs remained viable with a normal appearance, even at the highest concentration employed (1000μg/ml) (Fig. 1A,   Supplementary Fig. 1 ). We next examined the kinetics of AICAR-induced HSC cell death. For this purpose, HSC viability was assessed over a 24h time course following application of 500 μM AICAR. Cell density began to decrease as early as 3h after AICAR administration, with progressive loss of viable cells until near complete cell death occurred by 24h (Fig. 1B) . This loss of cell viability occurred coincident with an increase in caspase 3/7 activity, consistent with an induction of cell apoptosis (Fig. 1C) . These results suggest that AICAR and metformin have distinct impacts on quiescent HSC survival.
Previous studies have reported that treatment with AMPK activators AICAR and metformin results in a dose-dependent increase in Thr-172 phosphorylation of α-AMPK in activated HSC (17) . A difference in AMPK phosphorylation could potentially account for the distinct responses to AICAR and metformin in quiescent HSC. We therefore compared the timecourse of α-AMPK Thr-172 phosphorylation in quiescent HSC treated with AICAR or metformin. Western immunoblot analysis demonstrates maximal induction of Thr-172 phosphorylation of α-AMPK in quiescent HSCs treated with either of these drugs after 2 hours (Fig. 1D) . This result implies that the extent of AMPK activation does not explain the different outcomes of these treatments. (Fig. 1E) . While HSC activation through AMPK-independent pathways (vitamin D signaling (27) , TGF-β 1 signaling (28) and TLR4/LPS signaling (29)) did not significantly affect S6RP phosphorylation, AICAR and metformin treatment induced similar reductions in S6RP phosphorylation. Given this similarity in AICAR-and metformin-induced inhibition of mTOR signaling, it is unlikely that differential mTORC1 inhibition was responsible for the observed AICAR-induced cell death.
AICAR suppresses inflammatory gene expression in primary hepatic stellate cells
During liver injury various inflammatory mediators induce cell damage and apoptosis (29, 30).
We next explored the possibility that AICAR-induced cell death in HSCs was due to induction of proinflammatory chemokines/cytokines such as MCP-1 and IL-1β. Contrary to our expectation, MCP-1 and IL-1β gene expression progressively decreased in HSCs upon AICAR treatment ( Fig. 2A) . Expression levels of the metabolic genes PEPCK and LPL were found to increase with AICAR treatment, consistent with the know actions of AMPK activators (Supplementary Figure   2) . In addition, AICAR treatment completely abrogated lipopolysaccharide (LPS)-induced expression of MCP-1 and IL-1β, suggesting that proinflammatory factors do not play a role in this event (Fig. 2B) 
AICAR-induced HSC cell death parallels loss of Bambi and silencing of AMPK restores
Bambi expression and partially rescues HSCs from death
The TGF-β pseudoreceptor Bambi functions as a negative regulator of TGF-β signaling, a potent cytokine that is a prime mediator of hepatic fibrogenesis (31) . Downregulation of Bambi and consequent sensitization to TGF-β signaling is an integral component of HSC activation (29) .
As Bambi may function not only to promote the quiescent HSC phenotype, but also to promote quiescent HSC survival we wished to determine whether AICAR and metformin could elicit differential effects on Bambi expression, thereby altering HSC survival. Interestingly, expression levels of Bambi progressively declined over time in AICAR treated cells (Fig. 3A) . In contrast, metformin treatment induced an increase in Bambi expression for up to 10 h, followed by a return to baseline after 24-32 hrs (Fig. 3B) . These results suggested that differential expression of Bambi may account for the differences in HSC survival. To further examine the role of AMPK in Bambi expression and HSC survival, the effects of AICAR and metformin treatment were examined after prior siRNA knockdown of AMPK expression. AICAR treated control cells (500 μm AICAR for 15h after transfected with a scambled siRNA) appeared poised to undergo apoptosis/necrosis and expressed markedly reduced levels of Bambi, consistent with our earlier findings (Fig. 3C & D) . However, while HSCs lacking AMPK resembled control cells, these cells were partially rescued from AICAR-induced cell death and maintained normal levels of Bambi expression (Fig. 3C & 3D) . In contrast, siRNA knockdown of AMPK had little effect on the response of HSCs to metformin. A similar induction of Bambi was seen in control (transfected with scrambled siRNA) and AMPK knockdown cells, and no effect on cell viability was observed (Fig. 3E and data not shown) . Together these results suggest that AICAR-mediated HSC cell death is due in part to AMPK-dependent inhibition of Bambi expression, and that metformin-mediated HSC cell survival is attributable to an AMPK-independent increase in Bambi.
Cancer Research. 
Ectopic expression of Bambi improves HSCs survival upon treatment with AICAR
During the resolution phase of hepatic fibrosis, a crucial mechanism that operates to reduce injury is an increase in the apoptosis of activated HSC (32) . Given our finding that AICAR induces cell death/apoptosis in quiescent HSCs, we next asked whether this effect was mediated by changes in Bambi expression. HSCs transfected with siRNA targeting Bambi showed reduced viability, similar to that seem with AICAR treatment (Fig. 4A) . Furthermore, HSCs transfected with human BAMBI displayed increased resistance to AICAR-induced cell death (Fig. 4A) . As (Fig. 4A & 4B) , though Bcl-2 expression was diminished by AICAR independent of ectopic Bambi expression. In addition, siRNA-mediated reduction of Bambi had minor effects on TRAIL while significantly reducing the expression of anti-apoptotic Bcl-2 gene (Fig. 4B) . In HSCs treated with metformin TRAIL levels gradually decreased with time (Fig 4C) , suggesting that metformin functions differently to AICAR and is protective against TRAIL-dependent cell death. Furthermore, consistent with a pro-survival role for Bambi, siRNA knockdown of Bambi in HSCs resulted in a marked increase in caspase activity (Fig. 4D) .
Ectopic expression of Bambi induces the Wnt/β-catenin pathway in HSCs
Bambi has been shown to induce Wnt/β-catenin signaling in other cellular systems leading to cell proliferation and survival (33) . This prompted us to investigate whether Bambi-dependent partial rescue of AICAR-induced cell death was in part due to induction of the Wnt/β-catenin 
signaling pathway. Supporting this hypothesis, transfection of HSCs with increasing amounts of
Bambi significantly increased β-catenin mRNA and protein (Fig. 5A & 5B) . To confirm that Bambi augments the functional Wnt/β-catenin signaling pathway, quiescent HSC were transfected with a β-catenin-dependent TCF-4/ELF-binding luciferase reporter from the fibronectin promoter/enhancer. This reporter was induced several-fold by Bambi, demonstrating that a true activation of Wnt/β-catenin signaling operates in quiescent HSCs in response to heightened Bambi expression (Fig. 5A) . In addition, a reduced β-catenin expression was observed on Bambi knockdown (Fig. 5B) .
Bambi mRNA expression is stabilized by addition of cycloheximide in quiescent HSCs
In order to determine whether metformin acts directly to up-regulate Bambi, quiescent HSC were treated with metformin with and without cycloheximide, a de novo protein synthesis inhibitor.
Inhibition of protein synthesis markedly enhanced the induction of Bambi by metformin (Fig.   6A ), consistent with reported results (40). Interestingly, though the extent of stabilization of Bambi mRNA by cycloheximide in AICAR-treated cells was also significant, it was less robust, suggesting that different protein synthesis-independent regulatory mechanisms were operating.
In addition, metformin-mediated Bambi induction was not found in activated HSCs (Fig. 6B) 
Discussion:
Sustained AMPK activation by AICAR, metformin and adiponectin in activated HSCs has been linked to apoptosis (16, 34) . Similarly, AMPK-mediated cell death has been reported in other cell types treated with these AMPK-activators (35) . However, AICAR can induce apoptosis independent of AMPK through activation of the mitochondrial apoptotic pathway (36) 
